O
9
-2
SWKS
50
-2
NTRS
25
-5
APA
46
-3
NKE
25
-3
RRC
48
-2
SLG
38
-3
FDX
31
-2
FITB
40
-3
PYPL
41
16
MAT
41
-4
AN
50
-2
FCX
49
-3
DG
1
-8
BF.B
54
-5
XEL
53
3
FRT
34
-2
PCG
80
3
HRL
26
-12
WRK
33
11
O
9
-2
SWKS
50
-2
NTRS
25
-5
APA
46
-3
NKE
25
-3
RRC
48
-2
SLG
38
-3
FDX
31
-2
FITB
40
-3
PYPL
41
16
MAT
41
-4
AN
50
-2
FCX
49
-3
DG
1
-8
BF.B
54
-5
XEL
53
3
FRT
34
-2
PCG
80
3
HRL
26
-12
WRK
33
11
Financhill
Back

PTC Therapeutics 10K Form

Sell
33

PTCT
PTC Therapeutics

Last Price:
44.04
Seasonality Move:
20.28%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2020-08-05 10Q PTCT/PTC Therapeutics Quarterly
2020-04-30 10Q PTCT/PTC Therapeutics Quarterly
2020-03-02 10K PTCT/PTC Therapeutics Annual
2019-10-30 10Q PTCT/PTC Therapeutics Quarterly
2019-08-06 10Q PTCT/PTC Therapeutics Quarterly
2019-05-02 10Q PTCT/PTC Therapeutics Quarterly

Receive PTCT News And Ratings

See the #1 stock for the next 7 days that we like better than PTCT

PTCT Financial Statistics

Sales & Book Value

Annual Sales: $698.8M
Cash Flow: $-73.16M
Price / Cash Flow: 0
Annual Sales: $-6.18
Price / Book: 0

Profitability

EPS (TTM): -7.89000
Net Income (TTM): $-571.25M
Gross Margin: $654.12M
Return on Equity: 0%
Return on Assets: -33.63%

PTC Therapeutics Earnings Forecast

Key PTC Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 10 years for PTCT is 93.61%.
  • The Selling, General & Administrative Expenses for PTCT have been equal to 46.65% of Gross Profit Margin.
  • The Research & Development expenses have been 93.23% of Revenue.
  • The Interest Expense is -16.26% of Operating Income.
  • The Net Earning history of PTCT is -80.00% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 4 years.

PTC Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Healthcare
Current Symbol: PTCT
CUSIP: 69366J
Website: ptcbio.com

Debt

Debt-to-Equity Ratio: -1.25
Current Ratio: 1.39
Quick Ratio: 1.11

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PTCT Technical Analysis vs Fundamental Analysis

Sell
33
PTC Therapeutics (PTCT) is a Sell

Is PTC Therapeutics a Buy or a Sell?

  • PTC Therapeutics stock is rated a Sell
    The current PTC Therapeutics [PTCT] share price is $42.57. The Score for PTCT is 33, which is 34% below its historic median score of 50, and infers higher risk than normal.